Genmab Shares Climb on Positive Blood-Cancer Drug Study Results
Genmab shares jumped 8.3% after the company and partner AbbVie announced positive late-stage clinical trial results for their Epkinly drug in a common type of lymphoma. The drug helped extend the time patients lived without their disease worsening.
Genmab shares jumped after the biotechnology company and AbbVie said their Epkinly drug helped extend the time patients with a common type of lymphoma lived without the disease getting worse in a late-stage clinical trial. 3% in European morning trading.